GLOBAL ANTI-DEPRESSANT DRUGS, DEVICES, AND THERAPIES MARKET FORECAST 2017-2025

July 2017 | 145 pages | ID: GC92EC61BDAEN
Inkwood Research

Abstracts

KEY FINDINGS

The Global Anti-depressant drugs, devices, and therapies market is anticipated to grow at a CAGR of 2.12% over the forecast period of 2017- and 2025. The revenue generated by the market is expected to increase from $ 16442 million in 2016 and reach $19712 million by 2025. The anti-depressant drugs, devices, and therapies market is primarily driven because of factors such as a shift in the market from branded to generic drugs, a growing consciousness of depression as a medical disorder and the surge in sales of antidepressants in the past few years.

MARKET INSIGHTS

The market is segmented into types of antidepressants drugs, types of devices and the types of therapies.

Antidepressants drugs are further segmented into:

• Serotonin and norepinephrine reuptake inhibitors (SNRIs)
• Tricyclic antidepressants (TCA)
• Norepinephrine and dopamine reuptake inhibitors (NDRIs)
• Atypical antidepressants
• Monoamine oxidase inhibitors (MAOIs)
• Others

Devices are further segmented into:

• Deep Brain Stimulators
• Fisher Wallace Stimulators
• Transcranial Magnetic Stimulator
• Others

Therapies are further segmented into:

• Cognitive Behavior Therapy (CBT)
• Electroconvulsive Therapy (ECT)
• Rational-emotive behavior therapy (REBT)
• Others

The high cost for depression therapies coupled with the lack of medical insurance coverage for them is a major factor restraining the market growth. However, with the rising awareness about depression being a medical condition, the market is expected to show a huge promise during the forecasted years.

REGIONAL INSIGHTS

Geographically, the global anti-depressant drugs, devices, and therapies market is segmented into:

• North America - U.S. & Canada
• Asia-Pacific – China, India, Japan, Australia, Rest of APAC
• Europe - UK, France, Germany, Spain, Rest of Europe
• Rest of World

The North American market is expected to hold the biggest share by 2025 on account of its developed healthcare system and increased expenditure on mental health treatment. Major players such as Eli Lilly, Forest Laboratories, and Pfizer are based in North America. However, this market is facing a possibility of dilution on account of the patent expiry of most of the prescribed drugs. On the contrary, the Asia-Pacific market is expected to be the fastest-growing region for the anti-depressant drugs, devices, and therapies market. The level of awareness regarding depression is steadily increasing in countries such as India, China, Japan, and Korea, thus making this region a prospective market in the coming years.

COMPETITIVE INSIGHTS

Pfizer Inc. is a research-based, global biopharmaceutical company that deals with vaccines, medicines, and consumer healthcare products. TEVA Pharmaceutical Industries is another prominent generic pharmaceutical company that is engaged in the development, production, and marketing of generic, proprietary branded pharmaceuticals and active pharmaceutical ingredients. Some of the other major players include:

• Eli Lily
• Neuronetics
• Abbot Laboratories
• Allergan Plc
• Brainsway
• Cyberonics Inc
• Sun Pharmaceuticals
• Others

Contents

1. RESEARCH SCOPE

1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

2.1. SOURCES OF DATA
  2.1.1. SECONDARY DATA
  2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
2.5. ESTIMATION METHODOLOGY

3. EXECUTIVE SUMMARY

3.1. MARKET SUMMARY
  3.1.1. KEY FINDINGS
    3.1.1.1. STIFF COMPETITION BETWEEN GENERIC AND BRANDED DRUGS
    3.1.1.2. RISE IN THE NUMBER OF DEPRESSION PATIENTS AND INCREASING AWARENESS LEVEL OF THE ASIAN CONSUMERS
    3.1.1.3. A SHIFT IN THE MARKET FROM BRANDED TO GENERIC DRUGS

4. MARKET DYNAMICS

4.1. DRIVERS
  4.1.1. BRANDED DRUGS ARE OUTPERFORMING DUE TO HIGH COST COMPARED TO GENERIC DRUGS
  4.1.2. SWELLING CONSCIOUSNESS OF DEPRESSION AS A MEDICAL DISORDER
  4.1.3. SURGE IN SALES OF ANTIDEPRESSANTS
4.2. RESTRAINTS
  4.2.1. HIGH PRICE OF THE DEPRESSION THERAPY
  4.2.2. PATENT EXPIRATION FACED BY THE COMPANIES
  4.2.3. DELAY IN PRODUCT LAUNCHES
4.3. CHALLENGES
  4.3.1. STIFF COMPETITION FROM THE GENERIC DRUG MAKERS
4.4. OPPORTUNITIES
  4.4.1. HUGE MARKET POTENTIAL
  4.4.2. MORE INTENDED FOR PERSONNEL THERAPY AND DEVICES TREATMENT

5. SEGMENTATION

5.1. MARKET BY COMPONENTS 2017-2025
  5.1.1. MARKET BY ANTIDEPRESSANTS 2017-2025
    5.1.1.1. SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS)
    5.1.1.2. NOREPINEPHRINE AND DOPAMINE REUPTAKE INHIBITORS (NDRIS)
    5.1.1.3. ATYPICAL ANTIDEPRESSANTS
    5.1.1.4. MONOAMINE OXIDASE INHIBITORS (MAOIS)
    5.1.1.5. OTHER MEDICATIONS
  5.1.2. MARKET BY MENTAL HEALTH DEVICES
    5.1.2.1. GLOBAL DEEP BRAIN SIMULATOR MARKET
    5.1.2.2. FISHER WALLACE STIMULATOR
    5.1.2.3. TRANSCRANIAL MAGNETIC SIMULATOR (TMS)
    5.1.2.4. OTHER DEVICES
  5.1.3. MARKET BY THERAPIES 2017-2025
    5.1.3.1. COGNITIVE BEHAVIOR THERAPY (CBT)
    5.1.3.2. ELECTROCONVULSIVE THERAPY (ECT)
    5.1.3.3. RATIONAL EMOTIVE BEHAVIOR THERAPY (REBT)
    5.1.3.4. OTHER THERAPIES

6. KEY ANALYTICALS

6.1. PORTERS 5 FORCES MODEL
  6.1.1. THREAT OF NEW ENTRANTS
  6.1.2. THREAT OF SUBSTITUTE PRODUCTS
  6.1.3. BARGAINING POWER OF BUYER
  6.1.4. BARGAINING POWER OF SUPPLIER
  6.1.5. INTENSITY OF COMPETITIVE RIVALRY
6.2. ESTIMATION ANALYSIS
  6.2.1. INCREASING PREVALENCE OF MENTAL HEALTH PROBLEMS
  6.2.2. RISING HEALTHCARE EXPENDITURE ACROSS THE GLOBE
  6.2.3. RISING GERIATRIC POPULATION
6.3. VALUE CHAIN ANALYSIS
  6.3.1. FOR DRUGS
    6.3.1.1. MANUFACTURERS
    6.3.1.2. DISTRIBUTORS
    6.3.1.3. RETAILERS
    6.3.1.4. END-USERS
  6.3.2. FOR DEVICES
    6.3.2.1. MANUFACTURERS
    6.3.2.2. DISTRIBUTORS
    6.3.2.3. END-USERS
6.4. KEY BUYING CRITERIA
6.5. OPPORTUNITY MATRIX
6.6. VENDOR LANDSCAPE

7. GEOGRAPHY

7.1. NORTH AMERICA
  7.1.1. UNITED STATES
  7.1.2. CANADA
7.2. EUROPE
  7.2.1. REGULATIONS AND REIMBURSEMENT POLICIES IN THE EUROPEAN UNION
  7.2.2. UNITED KINGDOM
  7.2.3. FRANCE
  7.2.4. GERMANY
  7.2.5. SPAIN
  7.2.6. REST OF THE EUROPE
7.3. ASIA PACIFIC
  7.3.1. CHINA
  7.3.2. INDIA
  7.3.3. JAPAN
  7.3.4. AUSTRALIA
  7.3.5. REST OF ASIA PACIFIC
7.4. REST OF WORLD

8. COMPANY PROFILE

8.1. COMPETITIVE ANALYSIS
  8.1.1. KEY STRATEGIES AND ANALYSIS
  8.1.2. MARKET SHARE ANALYSIS
  8.1.3. TOP COMPANY ANALYSIS
8.2. ABBOT LABORATORIES
8.3. ALLERGAN PLC
8.4. BOEHRINGER INGELHEIM GMBH
8.5. BRAINSWAY
8.6. CYBERONICS INC
8.7. ELI LILLY AND COMPANY
8.8. F. HOFFMANN-LA ROCHE LTD
8.9. GLAXOSMITHKLINE
8.10. H. LUNDBECK AS
8.11. MAYO CLINIC
8.12. NEURONETICS
8.13. PFIZER
8.14. SANOFI
8.15. SUN PHARMACEUTICALS
8.16. TEVA PHARMACEUTICALS INDUSTRIES

TABLE LIST

TABLE 1 GLOBAL ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET BY REGION 2017- 2025 ($ MILLION)
TABLE 2 PREVALENCE OF DEPRESSION IN WESTERN EUROPE IN 2016
TABLE 3 REGULATIONS AFFECTING DEPRESSION DRUGS AND THERAPY
TABLE 4 LANDSCAPE OF DRUG EXPIRY AND LAUNCHES IN THE UNITED STATES
TABLE 5 GLOBAL ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, BY COMPONENTS 2017-2025($ MILLION)
TABLE 6 GLOBAL ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET BY ANTIDEPRESSANTS 2017-2025($ MILLION)
TABLE 7 GLOBAL ANTIDEPRESSANTS MARKET BY GEOGRAPHY 2017-2025($ MILLION)
TABLE 8 MAJOR PLAYERS IN THE SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS MARKET
TABLE 9 PRICE OF BUPROPION (WELLBUTRIN)
TABLE 10 MAJOR PLAYERS OF THE NOREPINEPHRINE AND DOPAMINE REUPTAKE INHIBITORS
TABLE 11 PRICE OF TRAZODONE OF DIFFERENT STRENGTH
TABLE 12 MAJOR PLAYERS OF THE ATYPICAL ANTIDEPRESSANTS MARKET
TABLE 13 PRICE OF TOFRANIL OF DIFFERENT STRENGTH
TABLE 14 MAJOR PLAYERS OF THE TRICYCLIC ANTIDEPRESSANTS MARKET
TABLE 15 PRICE OF TRANYLCYPROMINE (PARNATE)
TABLE 16 MAJOR PLAYERS OF THE MONOAMINE OXIDASE INHIBITORS (MAOIS) MARKET
TABLE 17 MAJOR PLAYERS OF THE OTHER ANTIDEPRESSANTS MARKET
TABLE 18 GLOBAL DEPRESSION MARKET BY MENTAL HEALTH DEVICES 2017-2025($ MILLION)
TABLE 19 GLOBAL MENTAL HEALTH DEVICES MARKET BY REGIONS 2017-2025($ MILLION)
TABLE 20 MAJOR PLAYERS OF THE DEEP BRAIN SIMULATION MARKET
TABLE 21 MAJOR PLAYERS IN THE FISHER WALLACE SIMULATOR MARKET
TABLE 22 MAJOR PLAYERS OF THE TRANSCRANIAL MAGNETIC SIMULATOR MARKET
TABLE 23 MAJOR PLAYERS OF THE OTHER DEVICES MARKET
TABLE 24 GLOBAL THERAPIES MARKET 2017-2025($ MILLION)
TABLE 25 GLOBAL THERAPIES MARKET BY REGION WISE 2017-2025($ MILLION)
TABLE 26 GLOBAL ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET BY GEOGRAPHY 2017-2025($ MILLION)
TABLE 27 NORTH AMERICA ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, 2017-2025 ($ MILLION)
TABLE 28 EUROPE GLOBAL ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET BY COUNTRIES 2017-2025($ MILLION)
TABLE 29 ASIA PACIFIC ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET 2017-2025($ MILLION)
TABLE 30 KEY STRATEGIES FOLLOWED BY COMPANIES WITHIN ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET

FIGURE LIST

FIGURE 1 ADULTS AVAILED MENTAL HEALTH TREATMENT IN THE US
FIGURE 2 DYSTHYMIC DISORDER IN THE US
FIGURE 3 GLOBAL ANTIDEPRESSANTS DRUG MARKET IN 2017-2025($ MILLION)
FIGURE 4 ASIA PACIFIC ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET 2017-2025($ MILLION)
FIGURE 5 SAVINGS THROUGH GENERIC DRUG USAGE IN THE UNITED STATES IN 2010-2016 ($ BILLION)
FIGURE 6 GLOBAL ANTIDEPRESSANTS MARKET 2016 & 2025($ MILLION)
FIGURE 7 GLOBAL SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS MARKET 2017-2025($ MILLION)
FIGURE 8 GLOBAL NDRIS MARKET 2017-2025($ MILLION)
FIGURE 9 GLOBAL ATYPICAL ANTIDEPRESSANTS MARKET 2017-2025($ MILLION)
FIGURE 10 GLOBAL TRICYCLIC ANTIDEPRESSANTS MARKET 2017-2025 ($ MILLION)
FIGURE 11 GLOBAL MAOIS MARKET 2017-2025 ($ MILLION)
FIGURE 12 GLOBAL OTHER ANTIDEPRESSANTS MARKET 2017-2025($ MILLION)
FIGURE 13 GLOBAL MENTAL HEALTH DEVICES MARKET 2016 & 2025($ MILLION)
FIGURE 14 GLOBAL DEEP BRAIN SIMULATION MARKET 2017-2025($ MILLION)
FIGURE 15 GLOBAL FISHER WALLACE SIMULATOR MARKET 2017-2025($ MILLION)
FIGURE 16 GLOBAL TRANSCRANIAL MAGNETIC SIMULATORMARKET 2017-2025($MILLION)
FIGURE 17 GLOBAL TRANSCRANIAL MAGNETIC SIMULATORMARKET 2017-2025($ MILLION)
FIGURE 18 GLOBAL THERAPIES MARKET 2016 & 2025($ MILLION)
FIGURE 19 GLOBAL COGNITIVE BEHAVIOR MARKET 2017-2025($ MILLION)
FIGURE 20 GLOBAL ELECTROCONVULSIVE THERAPY MARKET 2017-2025($MILLION)
FIGURE 21 GLOBAL RATIONAL EMOTIVE BEHAVIOUR THERAPY MARKET 2017-2025($ MILLION)
FIGURE 22 GLOBAL OTHER THERAPIES MARKET 2017-2025($ MILLION)
FIGURE 23 PREVALENCE OF MENTAL HEALTH DISORDERS ACROSS THE GLOBE BETWEEN PERIOD 2012 AND 2020 (MILLION)
FIGURE 24 RISING GERIATRIC POPULATION ACROSS THE GLOBE FOR PERIOD 2014-2020 (MILLION)
FIGURE 25 VALUE CHAIN OF ANTIDEPRESSANT DRUGS
FIGURE 26 VALUE CHAIN ANALYSIS FOR DEVICE MARKET
FIGURE 27 GLOBAL ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET BY GEOGRAPHY 2016 & 2025($ MILLION)
FIGURE 28 UNITED STATES ANTIDEPRESSANTS DRUGS, DEVICES, AND THERAPIES MARKET 2017-2025($ MILLION)
FIGURE 29 CANADA ANTIDEPRESSANTS DRUGS, DEVICES, AND THERAPIES MARKET 2017-2025($ MILLION)
FIGURE 30 EUROPEAN ANTIDEPRESSANTS DRUGS, DEVICES, AND THERAPIES MARKET 2016 & 2025(%)
FIGURE 31 UNITED KINGDOM ANTIDEPRESSANTS DRUGS, DEVICES, AND THERAPIES MARKET 2017-2025($ MILLION)
FIGURE 32 FRANCE ANTIDEPRESSANTS DRUGS, DEVICES, AND THERAPIES MARKET 2017-2025($ MILLION)
FIGURE 33 GERMANY ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET 2017-2025($ MILLION)
FIGURE 34 SPAIN GLOBAL ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET 2017-2025($ MILLION)
FIGURE 35 CHINA ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET 2017-2025($ MILLION)
FIGURE 36 INDIA ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET 2017-2025($ MILLION)
FIGURE 37 JAPAN ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET 2017-2025($ MILLION)
FIGURE 38 AUSTRALIA ANTIDEPRESSANTS DRUGS, DEVICES, AND THERAPIES MARKET 2017-2025($ MILLION)
FIGURE 39 REST OF ASIA PACIFIC ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET 2017-2025($MILLION)
FIGURE 40 REST OF WORLD ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET 2017-2025($ MILLION)
FIGURE 41 MARKET SHARE OF ANTIDEPRESSANTS DRUG MANUFACTURERS (PERCENTAGE OF SALES), 2016